Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health
Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.
Clinical Trial Results by Menopausal Status
ATTAIN-1 Study (Obesity/Overweight Population)
Menopausal Stage
Maximum Weight Loss (lbs)
Maximum Weight Loss (%)
Premenopausal
28.0 lbs
12.8%
Perimenopausal
30.4 lbs
14.4%
Postmenopausal
28.2 lbs
14.1%
≥15% Weight Loss Achievers
Up to 51.5% of participants
ATTAIN-2 Study (Type 2 Diabetes Population)
Menopausal Stage
Maximum Weight Loss (lbs)
Maximum Weight Loss (%)
Premenopausal
23.4 lbs
11.3%
Perimenopausal
18.5 lbs
8.9%
Postmenopausal
27.8 lbs
13.6%
≥15% Weight Loss Achievers
Up to 44.2% of participants
Secondary Endpoints & Body Composition
Waist Circumference Reduction: Up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2 at week 72
Abdominal Fat Targeting: Clinically significant reduction in visceral adiposity, addressing menopause-specific fat distribution patterns
Metabolic Improvements: Enhanced insulin sensitivity and glycemic control in diabetic cohort
Durability: Sustained weight loss maintained through 72-week treatment period
Market Opportunity & Strategic Significance
Addressable Population: 1.2 billion women globally experiencing menopause-related metabolic challenges
Competitive Differentiation: First oral GLP-1 specifically demonstrating efficacy across all menopausal stages
Therapeutic Gap: Current weight management therapies show reduced efficacy in postmenopausal women due to hormonal changes
Commercial Potential: Premium positioning in women’s health segment of $100B+ GLP-1 market
Regulatory Timeline: NDA submission expected Q3 2026 with potential approval in H1 2027
Hormonal Interaction: Maintains efficacy despite estrogen decline and associated metabolic changes during menopause
Central vs. Peripheral Effects: Dual action on appetite regulation and peripheral metabolism overcomes menopausal resistance
Safety Profile: Favorable gastrointestinal tolerability compared to injectable GLP-1 analogs
Competitive Landscape Context
Parameter
Foundayo (Orforglipron)
Competing GLP-1 Therapies
Administration
Oral daily
Predominantly injectable
Menopausal Efficacy
Proven across all stages
Limited specific data
Abdominal Fat Reduction
4.3-4.9 inches
Variable, less documented
≥15% Weight Loss Rate
Up to 51.5%
Typically 30-40% range
Forward‑Looking Statements This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for Foundayo. Actual results may differ due to final regulatory decisions, competitive dynamics, market adoption rates, and evolving treatment guidelines.-Fineline Info & Tech
By Fineline Cube 